Motif Biosciences Raises $1M Series C Financing for Diabetes, Asthma Research | GenomeWeb
NEW YORK (GenomeWeb News) — Motif Biosciences has raised $1 million in series C financing to help pay for research into type 2 diabetes and asthma, partner company Amphion Innovations said today.
 
Amphion, which owns 47 percent of Motif, said it was responsible for $400,000 of the financing round.
 
in March, Motif reported receiving $1.8 million in financing, of which $500,000 came from Amphion.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.